Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial

发表于 2026-9-30 13:29:43

期刊：The Journal of Heart and Lung Transplantation

文献作者：Jason Weatherald; Mitesh V. Thakrar; Rhea A. Varughese; Mithum Kularatne; Jonathan Liu; Lea Harper; Omid Kiamanesh; Nowell Fine; Evan Orlikow; Chidera Nwaroh; Christina Thornton; John Swiston; Lisa Kolkman; Nathan W. Brunner; Doug Helmersen; Naushad Hirani

出版日期：2022-5-

DOI号：10.1016/j.healun.2022.01.002

下载链接：https://www.sciencedirect.com/sc ... 05324982200002X/pdf

文献链接：https://doi.org/10.1016/j.healun.2022.01.002

当前文献来源于 Elsevier BV。

备注信息：

发表于 2026-9-30 13:29:44

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[Elsevier/Sciencedirect] Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[Elsevier/Sciencedirect] Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial 一键复制